Acute myeloid leukemia (AML) is a heterogeneous disease with diverse clinical features, prognosis, and pathogenesis. Cytogenetic analysis is well accepted as one of the most important prognostic factors in AML. Using pretreatment cytogenetic analysis, risk stratification systems divide patients with AML into favorable, intermediate, and unfavorable risk groups. 1, 2 Complex karyotype has been strongly associated with unfavorable outcome in multiple studies. 1, 2 In the past, different definitions for complex karyotype have been used, which include three, four, or five unrelated cytogenetic abnormalities. [3] [4] [5] Most recently, Breems et al 6 proposed the concept of monosomal karyotype (MK), defined by the presence of at least two separate autosomal monosomies or one monosomy plus one or more structural abnormalities. Using this definition, different studies have confirmed that AML-MK Upon completion of this activity you will be able to:
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comprises a very poor prognostic subgroup of patients with AML. 6 In a study of 733 patients with AML with cytogenetic abnormalities, MK was shown to be a stronger prognostic predictor of poor outcome compared with the traditionally defined complex karyotype. 6 Patients with MK had a 4-year overall survival of 4% compared with 21% in patients with other unfavorable karyotypes but without MK. Other studies have also confirmed that MK is an independent predictor of very poor prognosis in the elderly. 7 In fact, this remains true even in a cohort of patients with only unfavorable cytogenetics. 8 The incidence and prognostic impact of MK had not been fully evaluated in the context of the 2008 World Health Organization (WHO) classification of AML. Kayser et al 9 found that in their cohort, AML-MK was significantly associated with myelodysplastic syndrome (MDS)-related cytogenetic abnormalities and AML with recurrent genetic abnormalities, but the authors did not include morphology in this analysis. The 2008 WHO approach classifies AML using genetic, immunophenotypic, biologic, morphologic, and clinical features. We have recently shown that the newly expanded AML with myelodysplasia-related changes (AML-MRC) group has a worse prognosis compared with AML not otherwise specified. The relationship of MK with AML-MRC has not been described, to our knowledge.
Recently, efforts in the classification of AML have focused on identifying molecular markers with prognostic significance. Few studies have evaluated the correlation between these markers and MK. Of the molecular markers described in AML and investigated in MK, NPM1 and FLT3 were found at very low frequencies in AML-MK. 9 CEBPA and WT1 mutational status in MK has not been reported. The goal of this study is to describe clinical, morphologic, cytogenetic, and molecular features of AML-MK in a group of patients with AML.
Materials and Methods

Patients
A total of 111 consecutive de novo patients with AML diagnosed at Stanford University Medical Center between May 2005 and November 2007 with adequate material for mutation analysis were studied as previously described. 10 All cases were diagnosed with bone marrow aspirates, blood smears, trephine biopsies, and/or flow cytometry according to 2008 WHO criteria. 11 Clinical parameters, hemogram data, and flow cytometry results at the time of diagnosis were reviewed. Clinical follow-up information was obtained by retrospective review of the electronic charts. Cytogenetic risk group stratification was performed using Southwest Oncology Group criteria. 3 This study has been approved by Stanford University's Institutional Review Board.
NPM1, FLT3, and CEBPA Mutational Analysis
Genomic DNA was obtained from the Stanford Molecular Pathology Laboratory. The FLT3-ITD, FLT3-D835, and exon 12 NPM1 insertion mutations were detected by a multiplex polymerase chain reaction (PCR) followed by restriction enzyme digestion and capillary electrophoresis. The entire coding region of CEBPA was PCR amplified and sequenced. 10
WT1 Mutation Analysis
Genomic DNA obtained from the Stanford Molecular Pathology Laboratory was added to a PCR mixture containing PCR buffer, MgCL₂, Q Solution, HotStarTaq DNA polymerase (all from Qiagen, Valencia, CA), dNTP (Thermo Fisher Scientific, Waltham, MA), DNase and RNase-free H₂O, and forward and reverse primers. The cycles included 95°C for 15 minutes followed by 35 cycles at 94°C for 60 seconds, 59°C for 45 seconds, 72°C for 60 seconds, and then a final extension at 72°C for 10 minutes. PCR products were treated with USB ExoSAP-IT (Affymetrix, Sunnyvale, CA). The treated PCR products were then sequenced with the BigDye v.3.1 sequencing kit (Applied Biosystems, Foster City, CA) and forward or reverse primers. The sequencing reactions were then purified with Performa DTR gel filtration cartridges (EdgeBio, Gaithersburg, MD) and run on an ABI 3100 sequencer and analyzed using ABI's Sequencing Analysis 5.1 software (Applied Biosystems).
Statistical Analysis
Overall survival (OS), disease-free survival (DFS), and complete response (CR) were defined as previously described. 12, 13 These parameters were compared using Kaplan-Meier methods and the log-rank test. Univariate and multivariate Cox proportional hazards models were performed. Quantitative factors were treated as continuous variables in these regression models. Categorical variables were compared using the Fisher exact test.
Results
Overall AML Group
In total, 111 patients, including 63 men and 48 women with a median age of 57 years (range, 17-83 years), were studied. Stratification of patients into cytogenetic risk groups resulted in 15 patients with favorable, 72 with intermediate, and 24 with unfavorable cytogenetic risk status. Most patients received idarubicin and cytarabine or daunorubicin and cytarabine as induction therapy and high-dose or standard-dose cytarabine for consolidation. The median OS was 171 days, and the median DFS was 82 days. CR was achieved in 64 (61%) of 105 patients.
Frequency of MK and Relationship With Complex Karyotype
Cytogenetic analysis was successful in all 111 patients with AML with 20 metaphases. A total of 14 (13%) patients with AML had MK as defined by Breems et al, 6 with either (1) loss of two or more distinct autosomal chromosomes or (2) one single autosomal chromosome in the presence of other structural abnormalities. Five (36%) of 14 patients had a loss of a single chromosome in the presence of other structural abnormalities, and the rest had a loss of two or more chromosomes. The most common chromosomes that were lost were chromosomes 7 and 17, which were present in 6 (43%) of all 14 patients with MK ❚Table 1❚. Most of the patients with MK (13 of 14) had a complex karyotype (as defined by having three or more unrelated changes).
Clinical Features and Course of Patients With AML-MK
Compared with other patients with AML, patients with MK were older at presentation (65 vs 54 years, P = .0025), and of patients older than 60 years, MK was frequent, seen in 11 (22%) of 49 patients. Review of hemogram data showed that patients with MK had a lower WBC count, while no difference in hemoglobin or hematocrit was found ❚Table 2❚. Patients with MK had lower bone marrow blast counts, and their blasts more frequently lacked CD34 (Table  2 ). There was no association of MK with sex (P = .567).
Using the 2008 WHO classification, 13 (93%) of 14 patients with MK were classified as having AML-MRC (P = .0030). Within this group, 3 (27%) of 11 patients had a reported history of MDS. Morphologic evaluation of the diagnostic bone marrow showed dysplasia in all three lineages in four (29%) patients and two lineages in nine (64%) patients of all MK cases. An example of AML-MK and multilineage dysplasia is illustrated in ❚Image 1A❚ and ❚Image 1B❚. One of the patients with MK had history of chemotherapy, which was considered therapy-related AML.
Review of the prognostic molecular data in this group of patients with AML showed that patients with MK significantly lacked NPM1 and FLT3-ITD mutations with no differences in the distribution of D835, WT1, and CEBPA mutations ❚Table 3❚, although the overall number of patients with CEBPA and WT1 mutations was small. Within the AML-MRC group, those with MK sought treatment at an older age (65 vs 60 years, P = .0412) and with lower marrow blasts (35% vs 47%, P = .0371), but no difference in presenting CBC was noted in this group.
In univariate analysis, outcome data showed that patients with AML-MK had worse OS (P = .001) and DFS (P = .007) ❚Figure 1❚. Fewer patients with MK achieved complete remission (five of 14; 36% vs 61%; P = .0211). When patients with MK were subdivided by number of chromosomes lost, no clinical difference was found between those who lost one chromosome or two or more (OS, P = .235). Within the AML-MRC group, patients with MK had shorter OS (P = .0089), shorter DFS (P = .0076), but no clinical difference in CR (P = .312) ❚Figure 2❚. In multivariate analysis, cytogenetic risk group, MK, and age 60 years or older all correlated with decreased survival (all P < .01) ❚Table 4❚. 
Discussion
It has long been accepted that AML with complex karyotype predicts an unfavorable prognosis. Recently, numerous studies have shown that MK is often associated with complex karyotype and predicts a very poor prognosis in AML. The overall frequency of MK in AML varies from 6% to 10% in previous studies but has been reported up to 20% in patients with AML older than 60 years. 7 In our study, AML-MK accounted for 13% of all patients with AML and 22% of all patients with AML 60 years and older. This difference in the reported rate of MK might be related to various techniques used in different laboratories. For instance, Haferlach et al 13 used 24-color fluorescence in situ hybridization in addition to chromosome banding. In addition, the distribution of various types of patients with AML in each study is different.
Compared with other patients with AML, patients with MK in our study also had lower counts and a higher frequency of previous MDS (27% of all patients). However, even when limiting analysis to only patients in the poor-prognosis AML-MRC group, patients with AML-MK had lower counts. This confirms the poor prognosis of this group but suggests that most patients with MK may have had MDS, although only three (27%) patients had a reported history of MDS. In addition to presenting with low counts, patients with AML-MK had blasts with a lower rate of CD34 expression. Most of the previous studies on AML-MK did not compare blast immunophenotype. A recent study suggested that CD11b was strongly associated with MK, but other antigens were not significantly expressed in comparison with other AML types. 14 The authors found that in addition to MK and complex karyotype, patients with AML with CD11b were also older and had an inferior OS. While we did not assess for CD11b expression in these cases of AML, our results are nonetheless in concordance with those of Chen et al 14 NPM1 mutations have been reported to be associated with more favorable prognosis in the absence of FLT3 mutation, which might explain their absence in this group. However, the presence of an FLT3 mutation is usually associated with worse survival in AML, which suggests that MK would provide additional information and might be defining a separate group of patients with a worse prognosis. In this study, similar to previous studies, AML-MK was associated with worse OS, DFS, and CR. Furthermore, even when restricting the group to just AML-MRC, patients with MK had significantly worse OS and DFS. However, in our group, there are too few patients without an associated complex karyotype, and therefore in our analysis, there is a strong association between MK and complex karyotype, and the two are not independent. This might be related to the small number of patients with MK in this study, but the frequency of MK in our patient group is similar to what is found in other studies. Perrot et al 8 found that MK retained independent significance only in OS and CR. In summary, MK appears to define a poor-prognosis group that is more frequent in older patients with AML. It is most commonly associated with a complex karyotype and other, previously recognized unfavorable cytogenetic abnormalities. In this study, it is not independent of complex karyotype, but further investigations are needed to evaluate this point.
